Simvastatin
| Evidence Level: L1 | Predicted Indications: 8 |
Table of Contents
Using the report as specified—flagging upfront that the evidence pack itself notes this “new indication” (familial hypercholesterolaemia) is not a genuine repurposing candidate but an already-established statin indication, and that several data gaps (UK licensing, MOA, SmPC safety data) are blocking.
Simvastatin: From Hypercholesterolaemia to Familial Hypercholesterolemia
One-Sentence Summary
Simvastatin is an HMG-CoA reductase inhibitor originally used to treat hypercholesterolaemia and mixed dyslipidaemia. The TxGNN model predicts it may be effective for Familial Hypercholesterolemia, with 18 clinical trials and 17 publications currently supporting this direction — although, as detailed below, this is not a true repurposing signal but confirmation of an already-established statin indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypercholesterolaemia / mixed dyslipidaemia (established statin-class indication; not captured in the current UK licensing data supplied — see gap below) |
| Predicted New Indication | Familial Hypercholesterolemia |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L1 |
| UK Market Status | Not Marketed (per evidence pack — see note under UK Market Information) |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack (original_moa is a recorded data gap, DG002). However, the repurposing rationale supplied alongside the top prediction is itself informative: Simvastatin is an HMG-CoA reductase inhibitor that directly blocks the hepatic cholesterol biosynthesis pathway. In patients with familial hypercholesterolaemia (FH), a defect in the LDL receptor causes LDL-C accumulation; statins upregulate hepatic LDL receptor expression, which is a well-established pharmacological mechanism rather than a speculative TxGNN association.
Importantly, the evidence pack’s own annotation for this candidate states this explicitly: “此為 statin class 之標準適應症，非典型老藥新用案例” — this is a standard indication for the statin class, not a typical repurposing case. In other words, the high TxGNN score here reflects that statins (including simvastatin) are already guideline-recommended first-line therapy for FH, rather than uncovering a genuinely novel therapeutic use. This should temper how the “Proceed with Guardrails” decision is interpreted — the guardrails relate to confirming licensing/safety documentation, not to establishing efficacy, which is already well demonstrated.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT01623115 | Phase 3 | Completed | 486 | Placebo-controlled RCT of alirocumab added to existing lipid-modifying therapy (incl. statins) in heterozygous FH not adequately controlled |
| NCT00552097 | Phase 3 | Completed | 720 | ENHANCE trial: ezetimibe + high-dose simvastatin vs simvastatin alone on carotid atherosclerosis progression in heterozygous FH |
| NCT03510715 | Phase 3 | Completed | 18 | Alirocumab efficacy/safety on LDL-C in children/adolescents with homozygous FH, on top of background treatment (incl. statins) |
| NCT00145574 | Phase 4 | Completed | 194 | Colesevelam added to stable-dose statin (incl. simvastatin) in paediatric heterozygous FH |
| NCT00129402 | Phase 3 | Completed | 248 | Ezetimibe + simvastatin vs simvastatin alone in adolescents with heterozygous FH |
| NCT00654446 | Phase 3 | Completed | 442 | Renal effects of rosuvastatin vs simvastatin in Fredrickson Type IIa/IIb dyslipidaemia, including heterozygous FH |
| NCT03885921 | Phase 3 | Completed | 44 | Long-term safety/tolerability of ezetimibe added to atorvastatin or simvastatin in homozygous FH |
| NCT01709500 | Phase 3 | Completed | 249 | Placebo-controlled RCT of alirocumab in heterozygous FH inadequately controlled on lipid-modifying therapy |
| NCT02107898 | Phase 3 | Completed | 216 | Alirocumab as add-on to stable statin therapy vs placebo in heterozygous FH / high CV risk hypercholesterolaemia |
| NCT01954394 | Phase 3 | Completed | 986 | Long-term open-label extension assessing safety/efficacy of alirocumab in heterozygous FH |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18376000 | 2008 | RCT | N Engl J Med | ENHANCE: simvastatin with or without ezetimibe in FH — landmark trial on atherosclerosis progression |
| 31696945 | 2019 | Review (Cochrane) | Cochrane Database Syst Rev | Systematic review of statins (incl. simvastatin) for children with FH |
| 15794711 | 2005 | Review | Expert Opin Drug Saf | Benefits and risks assessment of simvastatin specifically in FH |
| 41824552 | 2026 | Guideline | Circulation | 2026 ACC/AHA dyslipidaemia management guideline (retires 2018 cholesterol guideline) |
| 27417002 | 2016 | Observational | J Am Coll Cardiol | Statins in FH: association with reduced CAD events and all-cause mortality |
| 12908847 | 2003 | Review | Drug Saf | Benefits and risks of simvastatin specifically in FH patients |
| 11383320 | 2001 | Comparative study | Nutr Metab Cardiovasc Dis | Atorvastatin vs simvastatin for LDL-C goal attainment in heterozygous FH |
| 35629051 | 2022 | Observational | J Clin Med | Cellular immunity parameters in children with FH treated with simvastatin |
| 35361995 | 2022 | Observational | Pharmacogenomics J | Combined FH/statin pharmacogenomic genetic testing implementation study |
| 30270066 | 2018 | Observational | Atherosclerosis | Real-world FH treatment patterns and LDL-C goal attainment (Slovakia) |
UK Market Information
No marketing authorisation records were returned in this evidence pack (0 licenses, market status recorded as “Not Marketed”). This is notable, since simvastatin is a widely used generic statin in UK clinical practice under multiple manufacturers — this likely reflects a gap in the underlying regulatory dataset rather than genuine absence from the UK market. This should be verified directly against the MHRA products database / current BNF listing before any decision is finalised.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: the safety dataset in this evidence pack returned no warnings, contraindications, or drug interactions (all fields recorded as data gaps, DG001 — Blocking). This is a critical omission for a statin, given the well-known class risks of myopathy/rhabdomyolysis and CYP3A4-mediated interactions (e.g. with protease inhibitors, as surfaced incidentally in this pack’s HIV-related literature search). This gap must be closed before clinical use.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Evidence level L1 is supported by multiple completed Phase 3 RCTs (notably ENHANCE, NCT00552097/PMID 18376000) directly evaluating simvastatin in FH populations. However, this is not a novel repurposing signal — it confirms an already-established statin-class indication — and two data gaps are currently blocking or high-severity: missing SmPC warnings/contraindications (DG001, Blocking) and missing MOA documentation (DG002, High).
To proceed, the following is needed:
- TFDA/MHRA-equivalent SmPC warnings and contraindications (DG001 — blocking; required before any S1 safety assessment)
- Confirmed drug-drug interaction data, particularly CYP3A4-mediated interactions (myopathy/rhabdomyolysis risk)
- Verification of actual current UK marketing authorisation status via MHRA (the “0 licenses / not marketed” result is inconsistent with simvastatin’s known widespread UK generic availability and should be re-checked)
- Formal mechanism of action documentation (DG002)
- Clarification of whether “familial hypercholesterolemia” should be scored/tracked as a genuine repurposing candidate, given it is already a guideline-recommended statin indication rather than a new therapeutic use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.